Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19457857 | 1.00 | KCNJ1 (1.00) | KCNJ1KCNH2 | |
| Tartaric Acid SCHEMBL30378057 | 0.97 | KCNJ1 (0.93) | KCNJ1KCNH2 | |
| SCHEMBL20873045 | 0.95 | KCNJ1 (0.90) | KCNJ1KCNH2 | |
| SCHEMBL20873043 | 0.95 | KCNJ1 (0.90) | KCNJ1KCNH2 | |
| SCHEMBL19457878 | 0.94 | KCNJ1 (1.00) | KCNJ1KCNH2 | |
| SCHEMBL19457879 | 0.94 | KCNJ1 (1.00) | KCNJ1KCNH2 | |
| SCHEMBL19457859 | 0.92 | KCNJ1 (0.85) | KCNJ1KCNH2 | |
| SCHEMBL19457703 | 0.92 | KCNJ1 (0.85) | KCNJ1KCNH2 | |
| SCHEMBL15757966 | 0.92 | KCNJ1 (0.85) | KCNJ1KCNH2 | |
| SCHEMBL15757970 | 0.92 | KCNJ1 (0.85) | KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123135-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AS RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-04-23 | — | — | US | claimed |
| EP-3466945-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AS RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-04-10 | — | — | EP | claimed |
| US-11059810-B2 | Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-07-13 | — | — | US | disclosed |
| US-11059810-B2 | Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-07-13 | — | — | US | disclosed |
| EP-3231802-B1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-05-05 | — | — | EP | disclosed |
| EP-3231802-B1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-05-05 | — | — | EP | disclosed |
| US-20200347039-A1 | CRYSTAL FORM OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR AND PREPARATION METHOD THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| EP-3722293-A1 | CRYSTAL FORM OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR AND PREPARATION METHOD THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-10-14 | — | — | EP | disclosed |
| US-10759788-B2 | Pharmaceutical uses of pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-10759788-B2 | Pharmaceutical uses of pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-20200123135-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AS RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-04-23 | — | — | US | disclosed |
| US-20190152959-A1 | PROCESSES FOR PREPARING PYRIDINE CARBOXAMIDE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3466945-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AS RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| EP-3466945-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AS RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017211271-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AS RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR | 江苏恒瑞医药股份有限公司 | 2017-12-14 | — | — | WO | disclosed |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
| EP-3231802-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2017-10-18 | — | — | EP | disclosed |
| EP-3231802-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2017-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152959-A1 | PROCESSES FOR PREPARING PYRIDINE CARBOXAMIDE DERIVATIVES | CPS1, PDXK, SDHA | KCNJ1 2381/4885KCNH2 1134/4885 |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | KCNK2, KCNJ2, KCNK5 | KCNJ1 7/4885KCNH2 15/4885 |
| US-11059810-B2 | Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor | KCNK10, CASK, KCNN2 | KCNJ1 6/4885KCNH2 20/4885 |
| US-20200123135-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AS RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR | KCNK10, CASK, KCNN2 | KCNJ1 6/4885KCNH2 20/4885 |
| US-20200347039-A1 | CRYSTAL FORM OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR AND PREPARATION METHOD THEREOF | KCNK3, KCNK4, KCNJ1 | KCNJ1 3/4885KCNH2 19/4885 |
| US-10759788-B2 | Pharmaceutical uses of pyridine carboxamide derivatives | CASK, PDXK, NADK | KCNJ1 9/4885KCNH2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.